Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
College of Science, Health and Engineering, La Trobe University, Melbourne, Australia.
JAMA Cardiol. 2019 Dec 1;4(12):1230-1238. doi: 10.1001/jamacardio.2019.3891.
IMPORTANCE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States. Despite substantial declines in CVD mortality rates during past decades, progress against cardiovascular deaths in midlife has stagnated, with rates increased in some US racial/ethnic groups. OBJECTIVE: To examine the trends in premature (ages 25-64 years) mortality from CVD from 2000 to 2015 by demographics and county-level factors, including education, rurality, and the prevalence of smoking, obesity, and diabetes. DESIGN, SETTING, AND PARTICIPANTS: This descriptive study used US national mortality data from the Surveillance, Epidemiology, and End Results data set and included all CVD deaths among individuals ages 25 to 64 years from January 2000 to December 2015. The data analysis began in February 2018. EXPOSURES: Age, sex, race/ethnicity, and county-level factors. MAIN OUTCOMES AND MEASURES: Age-standardized mortality rates and average annual percent change (AAPC) in rates by age, sex, race/ethnicity, and county-level factors (in quintiles) and relative risks of CVD mortality across quintiles of each county-level factor. RESULTS: In 2000 to 2015, 2.3 million CVD deaths occurred among individuals age 25 to 64 years in the United States. There were significant declines in CVD mortality for black, Latinx, and Asian and Pacific Islander individuals (AAPC: range, -1.7 to -3.2%), although black people continued to have the highest CVD mortality rates. Mortality rates were second highest for American Indian/Alaskan Native individuals and increased significantly among those aged 25 to 49 years (AAPC: women, 2.1%; men, 1.3%). For white individuals, mortality rates plateaued among women age 25 to 49 years (AAPC, 0.05%). Declines in mortality rates were observed for most major CVD subtypes except for ischemic heart disease, which was stable in white women and increased in American Indian/Alaska Native women, hypertensive heart disease, for which significant increases in rates were observed in most racial/ethnic groups, and endocarditis, for which rates increased in white individuals and American Indian/Alaska Native men. Counties with the highest prevalence of diabetes (quintile 5 vs quintile 1: relative risk range 1.6-1.8 for white individuals and 1.4-1.6 for black individuals) had the most risk of CVD mortality. CONCLUSIONS AND RELEVANCE: There have been substantial declines in premature CVD mortality in much of the US population. However, increases in CVD mortality before age 50 years among American Indian/Alaska Native individuals, flattening rates in white people, and overall increases in deaths from hypertensive disease suggest that targeted public health interventions are needed to prevent these premature deaths.
重要性:心血管疾病 (CVD) 是美国发病率和死亡率的主要原因。尽管过去几十年 CVD 死亡率大幅下降,但中年心血管死亡方面的进展已经停滞,一些美国种族/族裔群体的死亡率有所上升。 目的:通过人口统计学和县级因素(包括教育、农村程度和吸烟、肥胖和糖尿病的流行程度),研究 2000 年至 2015 年期间 25-64 岁人群 CVD 过早(年龄 25-64 岁)死亡率的趋势。 设计、地点和参与者:本描述性研究使用了美国国家死亡率数据,来自监测、流行病学和最终结果数据集,包括 2000 年 1 月至 2015 年 12 月期间年龄在 25 至 64 岁之间的所有 CVD 死亡。数据分析于 2018 年 2 月开始。 暴露:年龄、性别、种族/族裔和县级因素。 主要结果和措施:按年龄、性别、种族/族裔和县级因素(五分位数)以及每个县级因素五分位数的 CVD 死亡率的相对风险,评估死亡率的年龄标准化率和平均年百分比变化 (AAPC)。 结果:2000 年至 2015 年期间,美国有 230 万人在 25-64 岁之间死于 CVD。黑人、拉丁裔和亚洲及太平洋岛民的 CVD 死亡率显著下降(AAPC:范围为-1.7 至-3.2%),尽管黑人的 CVD 死亡率仍然最高。美洲印第安人/阿拉斯加原住民的死亡率居第二高,25-49 岁人群的死亡率显著上升(AAPC:女性,2.1%;男性,1.3%)。对于白人,25-49 岁的女性死亡率趋于平稳(AAPC,0.05%)。除缺血性心脏病外,大多数主要 CVD 亚型的死亡率均有所下降,白人女性的缺血性心脏病死亡率稳定,而美洲印第安人/阿拉斯加原住民女性的缺血性心脏病死亡率上升。在大多数种族/族裔群体中,高血压性心脏病的死亡率显著上升,而对于高血压性心脏病,除白人外,其他所有人群的死亡率都有所上升,而心内膜炎在白人个体和美洲印第安人/阿拉斯加原住民男性中的死亡率则有所上升。糖尿病患病率最高的县(五分位 5 与五分位 1 相比:白人个体的相对风险范围为 1.6-1.8,黑人个体的相对风险范围为 1.4-1.6),CVD 死亡率的风险最高。 结论和相关性:美国大部分地区的 CVD 过早死亡率都有大幅下降。然而,美国印第安人/阿拉斯加原住民中 50 岁前 CVD 死亡率的上升、白人死亡率的平稳以及高血压性疾病导致的总死亡率上升表明,需要有针对性的公共卫生干预措施来预防这些过早死亡。
JAMA Cardiol. 2019-12-1
JAMA Netw Open. 2020-2-5
Lancet Public Health. 2018-7-21
JAMA Oncol. 2022-8-1
JAMA Pediatr. 2018-12-3
JAMA Netw Open. 2020-2-5
JAMA Oncol. 2023-8-1
Transl Vis Sci Technol. 2025-8-1
JAMA Netw Open. 2025-6-2
Prev Med Rep. 2025-3-21
Rev Cardiovasc Med. 2024-10-11
Hypertension. 2024-12
Natl Vital Stat Rep. 2019-5
JAMA Cardiol. 2018-5-1
Hypertension. 2018-1-15